Panelists discuss how systemic therapy plays a crucial role in embolization-eligible hepatocellular carcinoma (HCC), ...

data from 119 patients suffering from HCC who had received immunotherapy treatment before a liver transplant were analyzed by the Geneva team in order to evaluate the rejection incidence of the ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the European Commission (EC) to treat hepatocellular carcinoma (HCC), the most common type of ...

An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy ...

Transplantation combined with immunotherapy to cure liver cancer. Hepatocellular carcinoma (HCC) is the most common type of liver cancer in Switzerland and worldwide. Immunotherap ...

Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee, chief executive officer and co-founder of Teclison ...

The EC has approved BMS Opdivo in combination with Yervoy as a first-line treatment for adults with unresectable or advanced ...

A research team led by Prof. Sun Cheng from the University of Science and Technology of China (USTC), in collaboration with ...